ArticleJournal of the American Heart Association2015
Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons.
Article in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Network-Based, Cross-Sectional Analysis of Drug-Related Problems Reveals a Strong Association of Possible Inappropriate Medication and Clinical Outcomes in Romanian Elderly Nursing Home Residents.Medical sciences (Basel, Switzerland) · 2026Article
- Association between sedative prescriptions after hospital discharge and falls and other adverse events in older adults: a population-based cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Article
- Acute cardiovascular effects associated with the use of prescription medications: A Danish nationwide screening study.British journal of clinical pharmacology · 2025Article
- Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.BMJ (Clinical research ed.) · 2024Article
- Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.Frontiers in neuroscience · 2023Review
- Cardiovascular disease in older people with serious mental illness: Current challenges and future directions.Frontiers in psychiatry · 2023Article
- A scoping review of perceptions from healthcare professionals on antipsychotic prescribing practices in acute care settings.BMC health services research · 2022Article
- Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study.Basic & clinical pharmacology & toxicology · 2022Article
- Severity in schizophrenia patients receiving atypical antipsychotic medications.Bioinformation · 2022Article
- Article
- Identification of psychiatric patients with high mortality and low medical utilization: a population-based propensity score-matched analysis.BMC health services research · 2020Article
- Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013.The international journal of neuropsychopharmacology · 2020Observational
- Association Between Antipsychotics and All-Cause Mortality Among Community-Dwelling Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder.The mental health clinician · 2018Article
- Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia.The mental health clinician · 2018Article
- An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?Drugs & aging · 2018Article
- Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms.European journal of clinical pharmacology · 2017Review
- A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia.Drugs & aging · 2016Review
- Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.Current topics in medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData from observational studies have raised concerns about the safety of treatment with antipsychotic agents (APs) in elderly patients with dementia, but this area has been insufficiently investigated. We performed a head-to-head comparison of the risk of major adverse cardiovascular events and noncardiovascular mortality associated with individual APs (ziprasidone, olanzapine, risperidone, quetiapine, levomepromazine, chlorprothixen, flupentixol, and haloperidol) in Danish treatment-naïve patients aged ≥70 years. METHODS AND
resultsWe followed all treatment-naïve Danish citizens aged ≥70 years that initiated treatment with APs for the first time between 1997 and 2011 (n=91 774, mean age 82±7 years, 35 474 [39%] were men). Incidence rate ratios associated with use of different APs were assessed by multivariable time-dependent Poisson regression models. For the first 30 days of treatment, compared with risperidone, incidence rate ratios of major adverse cardiovascular events were higher with use of levomepromazine (3.80, 95% CI 3.43 to 4.21) and haloperidol (1.85, 95% CI 1.67 to 2.05) and lower for treatment with flupentixol (0.54, 95% CI 0.45 to 0.66), ziprasidone (0.31, 95% CI 0.10 to 0.97), chlorprothixen (0.76, 95% CI 0.61 to 0.95), and quetiapine (0.68, 95% CI 0.58 to 0.80). Relationships were generally similar for long-term treatment. The majority of agents were associated with higher risks among patients with cardiovascular disease compared with patients without cardiovascular disease (P for interaction <0.0001). Similar results were observed for noncardiovascular mortality, although differences in associations between patients with and without cardiovascular disease were small.
conclusionsOur study suggested some diversity in risks associated with individual APs but no systematic difference between first- and second-generation APs. Randomized placebo-controlled studies are warranted to confirm our findings and to identify the safest agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.